Diridavumab

N/A

Report date: 2023/11/30 20:02:39

Base Information

Drug NameDiridavumab
Drug Alias NameJNJ-54235025CR-6261
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInfluenza virus hemagglutinin glycoproteins modulators
TargetsInfluenza virus hemagglutinin glycoproteins
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[13
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCrucell Holland Bv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsInfluenza, Human

Other Information

ATC CodeN/A
Related LinksWikipedia